Antivascular ultrasound therapy of primary liver neoplasia

原发性肝肿瘤的超声抗血管治疗

基本信息

批准号：
10063483
负责人：
CHANDRA M SEHGAL
金额：
$ 41.52万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-01-01 至 2022-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10063483
关键词：
Acoustics Affinity Age Angiogenesis Inhibitors Animal Model Animals Blood Vessels Blood flow Cancer Etiology Cells Cessation of life Clinical Clinical Trials Cytotoxic Chemotherapy Deposition Endothelial Cells Endothelium Energy Transfer Exposure to Feedback Frequencies Future Goals Heating Image Implant Incidence Individual Knowledge Laboratories Liver Liver neoplasms Malignant Neoplasms Measures Methods Microbubbles Microscopic Modeling Monitor Neoplasms Neoplasms in Vascular Tissue Outcome Outcome Study Patients Pharmacologic Substance Physical therapy Population Primary Malignant Neoplasm of Liver Primary carcinoma of the liver cells Process Rattus Research Role Sonication Source Techniques Technology Temperature Testing Time Tissues Translations Treatment Efficacy Ultrasonic Therapy Ultrasonic wave Ultrasonography Width absorption base cancer cell cancer therapy comparative computer studies contrast enhanced cost design human subject improved insight interest intravenous administration mathematical model neovascularization neovasculature novel novel strategies quantitative ultrasound response side effect simulation treatment optimization tumor tumor growth

项目摘要

ABSTRACT Hepatocellular carcinoma (HCC) accounts for 80 to 90% of primary liver cancer. It is the fifth most common malignancy and is the third most common cause of cancer-related death. This application will test the novel approach of antivascular ultrasound for treating HCC. Our preliminary studies show that low- level ultrasound with intensities comparable to those used in treating physiotherapy patients, when used with microbubbles, disrupts tumor neovasculature and improves the survival of animals with implanted tumors. The goals of the research are to demonstrate the efficacy of antivascular ultrasound for treating HCC, and to identify the conditions of treatment that have high efficacy as measured both by imaging and survival of the animals with implanted liver tumors. The proposal has three Specific Aims. Specific Aim 1 will investigate the relationship between blood flow and temperature change. Specific Aim 2 will determine the ultrasound exposure conditions that produce tumor antivascular activity at the lowest possible exposure to ultrasound. Specific Aim 3 will evaluate the short-term and the long term-term therapeutic efficacy of single and multiple ultrasound treatments. We anticipate that the knowledge gained from the proposed research will lead to a new form of antivascular or vascular disrupting treatment for HCC. Of particular interest would be the ability of antivascular ultrasound to treat non-resectable small and large cancers frequently observed clinical. Advantages include the simplicity and small cost of low-intensity ultrasound technology, the use of quantitative ultrasound imaging to assess and monitor therapeutic efficacy at the time of treatment, and fewer unwanted side effects from the low-intensity ultrasound therapy compared to cytotoxic therapies. We anticipate that the results of this study will facilitate the translation of a novel ultrasound technology to the treatment of patients with HCC.

抽象的肝细胞癌（HCC）占原发性肝癌的80％至90％。这是第五的常见的恶性肿瘤，是与癌症相关死亡的第三大最常见原因。此应用程序将测试用于治疗HCC的抗血管超声的新方法。我们的初步研究表明，低 - 使用与治疗物理疗法患者相当的强度的水平超声使用微泡，破坏肿瘤新生血管系统并改善动物的存活肿瘤。该研究的目标是证明抗血管超声治疗HCC的功效，以及确定通过成像和存活来测量的具有高疗效的治疗条件患有植入肝肿瘤的动物。该提案具有三个具体目标。具体目标1将研究血流之间的关系和温度变化。特定的目标2将确定产生的超声暴露条件肿瘤抗血管活性在最低暴露于超声的情况下。特定目标3将评估短期和多种超声处理的短期和长期治疗功效。我们预计从拟议的研究中获得的知识将导致一种新的抗血管形式或对HCC的血管破坏治疗。特别感兴趣的是抗血管的能力超声处理不可切除的大型和大型癌症，经常观察到临床。优点包括低强度超声技术的简单性和较小的成本，使用定量超声成像以评估和监测治疗时的治疗功效，而不必要的一面很少与细胞毒性疗法相比，低强度超声疗法的影响。我们预计这项研究的结果将有助于将新型超声技术转化为处理 HCC患者。

项目成果

期刊论文数量（18）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Machine learning improves early detection of liver fibrosis by quantitative ultrasound radiomics.

DOI：
10.1109/ius54386.2022.9957180
发表时间：
2022-10
期刊：
IEEE International Ultrasonics Symposium : [proceedings]. IEEE International Ultrasonics Symposium
影响因子：
0
作者：
Al-Hasani, Maryam;Sultan, Laith R.;Sagreiya, Hersh;Cary, Theodore W.;Karmacharya, Mrigendra B.;Sehgal, Chandra M.
通讯作者：
Sehgal, Chandra M.

Can Sequential Images from the Same Object Be Used for Training Machine Learning Models? A Case Study for Detecting Liver Disease by Ultrasound Radiomics.

DOI：
10.3390/ai3030043
发表时间：
2022-09
期刊：
AI (Basel, Switzerland)
影响因子：
0
作者：
通讯作者：

A novel quantitative approach to evaluate femoral head perfusion by contrast-enhanced ultrasound: A pilot study in infants with developmental dysplasia of the hip.

一种通过对比增强超声评估股骨头灌注的新定量方法：对患有发育性髋关节发育不良的婴儿进行的初步研究。

DOI：
10.1109/ius51837.2023.10307817
发表时间：
2023
期刊：
IEEE International Ultrasonics Symposium : [proceedings]. IEEE International Ultrasonics Symposium
影响因子：
0
作者：
Sultan,LaithR;Alves,AndressaGF;Morgan,TrudyA;Sridharan,Anush;Batley,Morgan;Darge,Kassa;Sankar,WudbhavN;Back,SusanJ
通讯作者：
Back,SusanJ

Dose-dependent effects of ultrasound therapy on hepatocellular carcinoma.

DOI：
10.1109/ius46767.2020.9251660
发表时间：
2020-09
期刊：
IEEE International Ultrasonics Symposium : [proceedings]. IEEE International Ultrasonics Symposium
影响因子：
0
作者：
Sultan LR;D'Souza JC;Karmacharya MB;Hunt SJ;Brice AK;Gade T;Wood AK;Sehgal CM
通讯作者：
Sehgal CM

Hydralazine augmented ultrasound hyperthermia for the treatment of hepatocellular carcinoma.